论文部分内容阅读
目的研究对2型糖尿病患者采用地特胰岛素联合格列齐特缓释片治疗对患者临床疗效及对肝肾功能的影响。方法选取我院近年收治的糖尿病2型患者共100例,随机分为对照组及观察组。对照组采用门冬胰岛素皮下注射治疗,观察组采用地特胰岛素皮下注射联合格列齐特缓释片口服方式治疗。对比两组患者肝肾功能、研究期间出现低血糖例数以及C肽在餐前与餐后检测值情况。结果两组患者肝肾功能无明显变化(P>0.05),观察组中出现低血糖病例数明显低于对照组(P<0.05)。C肽检测结果上治疗前组间对比无差异(P>0.05),治疗后均有所改善但观察组改善程度更大(P<0.05)。结论采用地特胰岛素联合格列齐特缓释片治疗2型糖尿病在疗效上优于门冬胰岛素治疗模式,且治疗安全性高,具有临床推广价值。
Objective To study the clinical efficacy and the effect on liver and kidney function of patients with type 2 diabetes treated with insulin detemir combined with gliclazide sustained-release tablets. Methods A total of 100 patients with type 2 diabetes treated in our hospital in recent years were randomly divided into control group and observation group. The control group received insulin aspart injection subcutaneously. The observation group was treated with insulin dextrose subcutaneously and gliclazide sustained-release tablets orally. Liver and kidney function was compared between the two groups. The number of hypoglycaemia during the study period and the C-peptide pre-meal and post-meal test values were compared. Results There was no significant difference in liver and kidney function between the two groups (P> 0.05). The incidence of hypoglycemia in the observation group was significantly lower than that in the control group (P <0.05). There was no significant difference in the results of C-peptide before treatment (P> 0.05), but after treatment, the improvement of C peptide was observed in the observation group (P <0.05). Conclusion The combination of insulin detemir and gliclazide sustained-release tablets in the treatment of type 2 diabetes mellitus is better than insulin aspart in the treatment model, and it has high safety and clinical value.